{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:13:05Z","timestamp":1770833585415,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr. Diabetes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Plasma xanthine oxidoreductase (XOR) activity is high in metabolic disorders such as diabetic mellitus, obesity, or overweight. Thus, this study investigated whether the XOR inhibitor, topiroxostat, affected body weight. Male db\/db mice were fed standard diets with or without topiroxostat for 4 weeks. Body weight and food intake were constantly monitored, along with monitoring plasma biochemical markers, including insulin and XOR activity. Additionally, hepatic hypoxanthine and XOR activity were also documented. Single regression analysis was performed to determine the mechanism. Topiroxostat treatment suppressed weight gain relative to the vehicle without any impact on food intake. However, the weight of fat pads and hepatic and muscle triglyceride content did not change. Topiroxostat decreased the plasma uric acid and increased hepatic hypoxanthine in response to the inhibition of XOR activity. Plasma ketone body and free fatty acid were also increased. Moreover, fat weight was weakly associated with plasma XOR activity in the diabetic state and was negatively associated with ketone body by topiroxostat. These results suggested that topiroxostat amplified the burning of lipids and the salvage pathway, resulting in predisposing the body toward catabolism. The inhibition of plasma XOR activity may contribute to weight loss.<\/jats:p>","DOI":"10.1038\/s41387-021-00155-2","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T10:14:06Z","timestamp":1618308846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2324-3569","authenticated-orcid":false,"given":"Takashi","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Nampei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayo","family":"Murase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6641-1062","authenticated-orcid":false,"given":"Seigo","family":"Akari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"155_CR1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/jdi.12870","volume":"10","author":"S Sunagawa","year":"2019","unstructured":"Sunagawa, S. et al. Activity of xanthine oxidase in plasma correlates with indices of insulin resistance and liver dysfunction in patients with type 2 diabetes mellitus and metabolic syndrome: a pilot exploratory study. J. Diabetes Investig. 10, 94\u2013103 (2019).","journal-title":"J. Diabetes Investig."},{"key":"155_CR2","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1253\/circj.CJ-18-0082","volume":"82","author":"M Furuhashi","year":"2018","unstructured":"Furuhashi, M. et al. Plasma xanthine oxidoreductase activity as a novel biomarker of metabolic disorders in a general population. Circ. J. 82, 1892\u20131899 (2018).","journal-title":"Circ. J."},{"key":"155_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40519-018-0490-5","volume":"25","author":"A Klisic","year":"2020","unstructured":"Klisic, A. et al. Body mass index is independently associated with xanthine oxidase activity in overweight\/obese population. Eat. Weight Disord. 25, 9\u201315 (2020).","journal-title":"Eat. Weight Disord."},{"key":"155_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1089\/chi.2013.0098","volume":"10","author":"KT Harrison","year":"2014","unstructured":"Harrison, K. T., Aaron, S. K., Andrea, M. M., Julia, S. & L\u2019Aurelle, A. J. Xanthine oxidase and cardiovascular risk in obese children. Child Obes. 10, 175\u2013180 (2014).","journal-title":"Child Obes."},{"key":"155_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1089\/chi.2015.0051","volume":"12","author":"KT Harrison","year":"2016","unstructured":"Harrison, K. T., Aaron, S. K., Claudia, K. F., Brandon, M. N. & L\u2019Aurelle, A. J. Weight loss mediated reduction in Xanthine oxidase activity and uric acid clearance in adolescents with severe obesity. Child Obes. 12, 286\u2013291 (2016).","journal-title":"Child Obes."},{"key":"155_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/osp4.164","volume":"4","author":"T Nakamura","year":"2018","unstructured":"Nakamura, T. et al. Gastric inhibitory polypeptide receptor antagonist, SKL-14959 suppressed body weight gain on diet-induced obesity mice. Obes. Sci. Pract. 4, 194\u2013203 (2018).","journal-title":"Obes. Sci. Pract."},{"key":"155_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ejphar.2016.03.055","volume":"780","author":"T Nakamura","year":"2016","unstructured":"Nakamura, T. et al. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db\/db mice. Eur. J. Pharmacol. 780, 224\u2013231 (2016).","journal-title":"Eur. J. Pharmacol."},{"key":"155_CR8","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2337\/db18-1198","volume":"68","author":"BH Daniel","year":"2019","unstructured":"Daniel, B. H. et al. Hepatocyte-specific ablation or whole-body inhibition of xanthine oxidoreductase in mice corrects obesity-induced systemic hyperuricemia without improving metabolic abnormalities. Diabetes 68, 1221\u20131229 (2019).","journal-title":"Diabetes"},{"key":"155_CR9","doi-asserted-by":"publisher","first-page":"F481","DOI":"10.1152\/ajprenal.00092.2009","volume":"297","author":"T Kosugi","year":"2009","unstructured":"Kosugi, T. et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db\/db mice. Am. J. Physiol. Ren. Physiol. 297, F481\u2013F488 (2009).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"155_CR10","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.2337\/db10-0916","volume":"60","author":"W Baldwin","year":"2011","unstructured":"Baldwin, W. et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 60, 1258\u20131269 (2011).","journal-title":"Diabetes"},{"key":"155_CR11","doi-asserted-by":"publisher","first-page":"27138","DOI":"10.1074\/jbc.M113.485094","volume":"288","author":"Y Tsushima","year":"2013","unstructured":"Tsushima, Y. et al. Uric acid secretion from adipose tissue and its increase in obesity. J. Biol. Chem. 288, 27138\u201327149 (2013).","journal-title":"J. Biol. Chem."},{"key":"155_CR12","doi-asserted-by":"publisher","first-page":"F625","DOI":"10.1152\/ajprenal.00140.2005","volume":"290","author":"T Nakagawa","year":"2006","unstructured":"Nakagawa, T. et al. A casual role for uric acid in fructose-induced metabolic syndrome. Am. J. Physiol. Ren. Physiol. 290, F625\u2013F631 (2006).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"155_CR13","doi-asserted-by":"publisher","first-page":"F710","DOI":"10.1152\/ajprenal.00454.2007","volume":"294","author":"LG Sanchez-Lozada","year":"2008","unstructured":"Sanchez-Lozada, L. G. et al. Effect of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am. J. Physiol. Ren. Physiol. 294, F710\u2013F718 (2008).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"155_CR14","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1096\/fasebj.4.9.2189777","volume":"4","author":"H Judith","year":"1990","unstructured":"Judith, H. Metabolic effects of dietary fructose. FASEB J. 4, 2652\u20132660 (1990).","journal-title":"FASEB J."},{"key":"155_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1161\/ATVBAHA.113.302214","volume":"34","author":"N Murakami","year":"2014","unstructured":"Murakami, N. et al. Mice heterozygous for the xanthine oxidoreductase gene facilitate lipid accumulation in adipocytes. Arterioscler. Thromb. Vasc. Biol. 34, 44\u201351 (2014).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"155_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cmet.2007.01.005","volume":"5","author":"KJ Cheung","year":"2007","unstructured":"Cheung, K. J. et al. Xanthine oxiroreductase is a regulator of adipogenesis and PPAR\u03b3 activity. Cell Metab. 5, 115\u2013128 (2007).","journal-title":"Cell Metab."},{"key":"155_CR17","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1101\/gad.1032702","volume":"16","author":"V Claudia","year":"2002","unstructured":"Claudia, V., Alistair, S. & Mario, R. C. The housekeeping gene xanthine oxidoreductase is necessary for milk fat droplet enveloping and secretion: gene sharing in the lactating mammary gland. Genes Dev. 16, 3223\u20133235 (2002).","journal-title":"Genes Dev."},{"key":"155_CR18","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1161\/01.RES.0000149571.96304.36","volume":"95","author":"T Ohtsubo","year":"2004","unstructured":"Ohtsubo, T., Rovira, I. I., Starost, M. F., Liu, C. & Finkel, T. Xanthine oxidoreductase is an endogenous regulator of cycrooxygenase-2. Circ. Res. 95, 1118\u20131124 (2004).","journal-title":"Circ. Res."},{"key":"155_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1272\/jnms.75.2","volume":"75","author":"K Okamoto","year":"2008","unstructured":"Okamoto, K. & Nishino, T. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FXY-051. J. Nippon Med. Sch. 75, 2\u20133 (2008).","journal-title":"J. Nippon Med. Sch."},{"key":"155_CR20","first-page":"1","volume":"6","author":"T Nakamura","year":"2019","unstructured":"Nakamura, T. et al. The influence of albumin on the plasma xanthine oxidoreductase inhibitory activity of allopurinol, febuxostat and topiroxostat: Insight into extra-urate lowering effect. Integr. Mol. Med. 6, 1\u20137 (2019).","journal-title":"Integr. Mol. Med."}],"container-title":["Nutrition &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41387-021-00155-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41387-021-00155-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41387-021-00155-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T14:17:55Z","timestamp":1669817875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41387-021-00155-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["155"],"URL":"https:\/\/doi.org\/10.1038\/s41387-021-00155-2","relation":{},"ISSN":["2044-4052"],"issn-type":[{"value":"2044-4052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"assertion":[{"value":"2 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"12"}}